A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523180-38-00

Enrollment

Registered

2026-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uncontrolled Moderate to Severe Eosinophilic Asthma

Brief summary

Change from baseline to Week 12 in pre-bronchodilator FEV1.

Detailed description

Change from baseline to Week 12 in post-bronchodilator FEV1., Change from baseline to Week 12 in ACQ-5 score, Change from baseline to Week 12 in the AQLQ(S) Global Score, Incidence of TEAEs, Incidence of treatment-emergent SAEs, Plasma PK parameter estimates of KT-621 derived from plasma concentration time data

Interventions

DRUGKT-621

DRUGPlacebo oral tablet matched to KT-621

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline to Week 12 in pre-bronchodilator FEV1.	—

Secondary

Measure	Time frame
Change from baseline to Week 12 in post-bronchodilator FEV1., Change from baseline to Week 12 in ACQ-5 score, Change from baseline to Week 12 in the AQLQ(S) Global Score, Incidence of TEAEs, Incidence of treatment-emergent SAEs, Plasma PK parameter estimates of KT-621 derived from plasma concentration time data	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 11, 2026